

## **PanGenomic Health Closes Private Placement to Settle Outstanding Debts in the Amount of \$1,075,000**

*Not for distribution to United States Newswire Services or for dissemination in the United States*

**Vancouver, British Columbia, May 27, 2024** – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce that the Company has completed its previously announced settlement of outstanding indebtedness in the amount of \$1,075,116 through a private placement offering (the “**Offering**”) of an aggregate of 21,502,320 units (the “**Units**”) of the Company at a price of \$0.05 per Unit.

Each Unit consists of one Class A Common share in the capital of the Company (each a “**Common Share**”) and one share purchase warrant (each a “**Warrant**”), with each Warrant being exercisable for one additional Common Share (a “**Warrant Share**”) at a price of \$0.10 per Warrant Share for a period of 24 months from the date of issuance. If the closing price of the Common Shares is greater than or equal to \$0.20 for a period of 10 consecutive trading days, the Company may accelerate the expiration of the Warrants to the date that is 30 days after the issuance of a news release announcing such acceleration. The indebtedness settled in the Offering consisted of cash loans advanced to the Company as well as trade payables owed by the Company.

The sale of the Units, and the Common shares and Warrant Shares thereunder, resulted in the issuance of more than 100% of the number of issued and outstanding Common Shares of the Company immediately prior to the Offering. The Canadian Securities Exchange (the “**CSE**”) approved the Company’s reliance on an exemption from the shareholder approval requirements in Section 4.6(2)(b) of CSE Policy 4 – *Corporate Governance, Security Holder Approvals and Miscellaneous Provisions* on the basis that the Company was in serious financial difficulty and that the Company’s sole independent director determined that the Offering was in the best interests of the Company and that it was not feasible to obtain securityholder approval in a timely manner. No Related Persons (as that term is defined in the policies of the CSE) participated in the Offering. Accordingly, the Company did not hold a vote of its shareholders to approve the sale of the Units under the Offering.

The securities issued pursuant to the Offering are subject to a four month plus one day hold period under applicable Canadian securities laws.

This news release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any applicable state securities laws. Such securities may not be offered or sold within the United States except pursuant to an effective registration statement under the U.S. Securities Act and the securities laws of any applicable state in the United States or pursuant to an available exemption from the registration requirements thereof.

### **About PanGenomic Health Inc.**

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company,

PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

For more information, please contact:

Jerry Lai, Investor Relations  
PanGenomic Health Inc.  
778 743 4642  
ir@pangenomic.com

Maryam Marissen, President & CEO  
PanGenomic Health Inc.  
778 743 4642  
info@pangenomic.com

*This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on [www.sedarplus.ca](http://www.sedarplus.ca).*